Physician profile
Michael D Mason
NPI 1477581437
$1,475,399.55
in general payments reported to CMS, 2019-2025
8 companies · $133K in 2025
The $133K reported for 2025 was more than what 94% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217K · 2020: $315K · 2021: $297K · 2022: $199K · 2023: $171K · 2024: $145K · 2025: $133K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $262K · Royalty Or License: $185K · Travel and Lodging: $629 · Food and Beverage: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $262,025.00 |
| Royalty Or License | $185,046.30 |
| Travel and Lodging | $629.00 |
| Food and Beverage | $233.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $606,687.34 | 2019-2025 | Mako, Triathlon, Restoration |
| Encore Medical, Lp | $345,768.74 | 2019-2025 | Djo Surgical |
| Signature Orthopaedics USA Corp | $343,365.53 | 2020-2021 | |
| Orthofix Medical, INC. | $120,067.97 | 2019-2025 | Pillar Sa, Physio-Stim |
| Alphatec Spine, INC | $59,168.35 | 2019-2024 | Solus Alif |
| Radlink, INC | $172.08 | 2019 | |
| Djo, LLC | $107.54 | 2019 | |
| Molnlycke Health Care US, LLC | $62.00 | 2023 | Mepilex Border Post-Op, Mepilex Border Ag, Mepitel Ag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.